Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (5.246.832 €): Penumbral Rescue by Normobaric O=O Administration in Patients With Inämic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial Hor 19.12.2016 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Penumbral Rescue by Normobaric O=O Administration in Patients With Inämic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial
Ischemic stroke (IS), caused by occlusion of arteries that supply blood to the brain, remains a leading cause of mortality and morbidity in the world. Disruption of blood and oxygen supply to the brain leads to neuronal death in the ischemic core within minutes. The hypoperfused tissue surrounding the ischemic core, the penumbra, is at high risk for infarction over time but still salvageable. Neuroprotective “bridgingâ€, sustaining the penumbra until reperfusion, may widen the therapeutic window, make recanalization treatments accessible to more patients and improve overall IS outcomes. As ischemic cell death is primarily mediated by hypoxia, increasing oxygen supply to the penumbra seems THE logical approach. In animal models of IS, normobaric hyperoxygenation (NBHO) significantly increased penumbral oxygen pressure and attenuated brain injury when initiated early after onset of ischaemia and vessel occlusion was transient (35 to 50% infarct volume reduction). The PROOF project now seeks to demonstrate that NBHO (high-flow 100% oxygen at >45 L/min via a non-rebreather mask, or FiO2=1.0 for intubation/ventilation) reduces infarct growth from baseline to 24 hours compared to standard treatment if administered ≤3 hours after onset of anterior circulation IS, in patients with proximal vessel occlusion and salvageable tissue at risk. The study is multi-center, adaptive phase-IIb, randomized, open-label with blinded-endpoint (PROBE design). The primary efficacy criterion will be infarct growth from baseline to 24 hours. Secondary endpoints will be NIHSS 24h, categorical shift in the pre-stroke modified Rankin Score, QoL and cognition at day 90. Potential surrogate biomarkers, health economics and societal impacts will be assessed. If NBHO proves its neuroprotective potential in this selected population, phase-III trials in all IS patients may be undertaken. Considering its low costs and ease of use, NBHO may impact stroke care worldwide.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Centre Hospitalier Universitaire Vaudois | 26.225 € |
| Eberhard Karls Universitaet Tuebingen | 1.539.209 € |
| Ecrin European Clinical Research Infrastructure Network | 368.008 € |
| Eppdata GmbH | 737.875 € |
| Fakultni Nemocnice U SV Anny V Brne | 76.692 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 776.503 € |
| Groupe Hospitalier Universitaire Paris Psychiatrie et Neurosciences | 103.347 € |
| HUS-Yhtyma | 117.901 € |
| Katholieke Universiteit Leuven | 159.625 € |
| KKS-Netzwerk e. V. -Netzwerk DER Koordinierungszentren FUR Klinische Studien | 0,00 € |
| Luxembourg Institute OF Health | 0,00 € |
| Masarykova Univerzita | 0,00 € |
| Stroke Alliance for Europe | 66.625 € |
| Universitaetsklinikum Tuebingen | 0,00 € |
| Universitatsklinikum Heidelberg | 1.270.874 € |
| Vastra Gotalandsregionen | 3.948,75 € |
Quelle: https://cordis.europa.eu/project/id/733379
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
